BVI diversifies product offering
Botswana Vaccine Institute (BVI) has announced plans to launch a top tier vaccine manufacturing plant as it seeks to diversify product offering and penetrate new markets.
The development is expected to prop-up the Institute grappling with sustainability of revenue due to over dependence on the Foot & Mouth (FMD) vaccine.
According to BVI blueprint for 2021-2025, which seeks to enhance operational efficiency and reposition BVI as a global centre of excellence to unlock Africa’s livestock sector, trimming over-reliance on FMD is key.
BVI wants to ensure that forty percent of the institute’s revenue comes from four non-FMD products, to avoid bottom line being badly affected in the absence of FMD outbreaks. This week, BVI will launch a new blending and filling facility, which will enable BVI to improve international compliance and increase production capacity.
“The blending and filling facility will further enable us to penetrate new markets, diversify our product offering and improve production, warehousing and distribution capacities,” said BVI General Manager, Andrew Madeswi.
“We guarantee our clients sound quality management systems and a customer-centric approach.
BVI must ensure competitive supply of high-quality product at adequate level of complexity and agility if it is to remain globally competitive,” he added. BVI was founded in 1978 with the strategic mandate of ensuring the sustainability of Botswana’s beef industry by controlling trans-boundary animal diseases as well as diseases of public health concern.